Clinical Trials Logo
  1. Home
  2. Tongue Cancer
  3. NCT02295540

Hypofractionated Radiation Therapy Followed by Surgery in Treating Patients With Advanced Squamous Cell Carcinoma of the Oral Cavity

Tongue Cancer Clinical Trial

Official title:
Preoperative Hypofractionated Radiation Followed by Surgery in Advanced Oral Cavity Squamous Cell Carcinoma

Clinical Trial Summary

This phase I/II trial studies how well hypofractionated radiation therapy followed by surgery works in treating patients with squamous cell carcinoma of the oral cavity that has spread to other places in the body. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects. Giving hypofractionated radiation therapy before surgery may shrink the tumor making it easier to be removed, may reduce the risk of the cancer coming back, and may be a better treatment for squamous cell carcinoma of the oral cavity.

Clinical Trial Description

PRIMARY OBJECTIVES: I. 2 year locoregional control for advanced oral cavity squamous cell carcinoma (SCC) treated with preoperative hypofractionated radiation followed by surgical resection. SECONDARY OBJECTIVES: I. Rate of pathologic complete response after preoperative hypofractionated radiation at both the primary site and lymph nodes (LN). II. Rate of radiologic complete and partial response (computed tomography [CT] neck with intravenous [IV] contrast performed before and after radiation therapy, judged per Response Evaluation Criteria In Solid Tumors [RECIST] 1.1 criteria). III. Grade III/IV/V toxicity both short term (from start of radiation to 60 days after surgery) and long term (more than 60 days after surgery). IV. Rate of flap complications: Rate of flap revisions, and complete revisions required. V. Molecular correlates. VI. Quantitative imaging correlates. OUTLINE: Patients undergo hypofractionated intensity-modulated radiation therapy (IMRT) every other day for up to 5 treatments. Patients then undergo surgery 7-14 days after the last radiation treatment. After completion of study treatment, patients are followed up every 3 months for 2 years. ;

Study Design

Related Conditions & MeSH terms

  • Carcinoma
  • Carcinoma, Squamous Cell
  • Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity
  • Stage III Verrucous Carcinoma of the Oral Cavity
  • Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity
  • Stage IVA Verrucous Carcinoma of the Oral Cavity
  • Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity
  • Stage IVB Verrucous Carcinoma of the Oral Cavity
  • Tongue Cancer
  • Tongue Neoplasms
Clinical Trial Details
NCT number NCT02295540
Study type Interventional
Source Rutgers, The State University of New Jersey
Contact
Status Withdrawn
Phase N/A
Start date August 2016
Completion date January 2020
View Details
See also
  Status Clinical Trial Phase
Completed NCT01469429 - Phase 1b Food Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer. Phase 1/Phase 2
Withdrawn NCT04041141 - Oral Stent Device for Radiation Treatments of Oral Cancers
Completed NCT00049283 - Erlotinib, Docetaxel, and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer Phase 1
Completed NCT00407810 - Cetuximab and Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Phase 2
Completed NCT00096512 - S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Phase 2
Completed NCT01637194 - Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cancer Phase 1
Completed NCT00033618 - Ixabepilone in Treating Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck Phase 2
Completed NCT01816841 - Direct Visual Fluorescence in Finding Oral Cancer in High-Risk Patients and Patients Undergoing Routine Dental Care N/A
Recruiting NCT04028479 - The Registry of Oncology Outcomes Associated With Testing and Treatment
Completed NCT04059861 - Ultrasound in Tongue Cancer- a Help to Decide Depth of Invasion and to Improve the Surgical Margin N/A
Recruiting NCT01854021 - Effects of Different General Anesthesia Methods on Immune Responses in Patients Undergoing Surgery for Tongue Cancer N/A
Completed NCT01816984 - PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Phase 1/Phase 2
Withdrawn NCT01674374 - Botanical Therapy in Treating Mucositis in Patients With Head and Neck Cancer Who Have Undergone Chemoradiation Therapy Phase 2
Terminated NCT01528137 - Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Head and Neck Cancer Phase 1
Completed NCT04337853 - Radiotherapy of Tongue Cancer Using an Intraoral Stent Phase 1
Completed NCT01806675 - 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy Phase 1/Phase 2
Active, not recruiting NCT01847326 - Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin Followed By Chemoradiation in Treating Patients With Recurrent Head and Neck Cancer Phase 1
Terminated NCT02177838 - Cetuximab and Radiation Therapy in Treating Patients With Stage III-IV Head and Neck Cancer N/A
Completed NCT00114283 - Lapatinib Ditosylate in Treating Patients With Metastatic or Recurrent Head and Neck Cancer Phase 2
Completed NCT04126226 - Quality of Life in Patients Treated for Tongue and/or Jaw Neoplasia Before and After Speech Therapy N/A